tbuckley/cabot-search huggingface dataset:
Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy
Authors: A.M. Oza, D. Cibula, A. Oaknin, C. Poole, R.H.J. Mathijssen, G.S. Sonke, N. Colombo, J. Špaček, P. Vuylsteke, H. Hirte, J. Pfisterer, M. Plante, L.C. Hanker, A. Fielding, V. Haddad, J. Chmielecki, M. Friedlander
Journal: Annals of Oncology (2018)
TRICC-C: Nintedanib vs. placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: Final results from the randomized phase II trial of the AIO
Authors: T.J. Ettrich, A.W. Berger, T. Decker, R.D. Hofheinz, V. Heinemann, T. Hoffmann, H.F. Hebart, T. Herrmann, C.-V. Hannig, P. Büchner-Steudel, H. Bartholomäus, M. Güthle, L. Perkhofer, T. Seufferlein
Journal: Annals of Oncology (2018)
Detection of mutations and copy number alterations in circulating DNA from pancreatic neuroendocrine tumor patients
Authors: G. Boons, K. Op de Beeck, T. Vandamme, M. Beyens, G. Roeyen, K. Janssens, K. Zwaenepoel, G. van Camp, M. Peeters
Journal: Annals of Oncology (2018)
Ultrasound molecular imaging as a non-invasive companion diagnostic for netrin-1 interference therapy in breast cancer
Authors: Jennifer Wischhusen, Katheryne E. Wilson, Jean-Guy Delcros, Rodolfo Molina-Peña, Benjamin Gibert, Shan Jiang, Jacqueline Ngo, David Goldschneider, Patrick Mehlen, Juergen K. Willmann, Frederic Padilla
Journal: Theranostics (2018)

In ultrasound molecular imaging (USMI), ligand-functionalized microbubbles (MBs) are used to visualize vascular endothelial targets. Netrin-1 is upregulated in 60% of metastatic breast cancers and promotes tumor progression. A novel netrin-1 interference therapy requires the assessment of netrin-1 expression prior to treatment. In this study, we studied netrin-1 as a target for USMI and its potential as a companion diagnostic in breast cancer models. Methods: To verify netrin-1 expression and localization, an in vivo immuno-localization approach was applied, in which anti-netrin-1 antibody was injected into living mice 24 h before tumor collection, and revealed with secondary fluorescent antibody for immunofluorescence analysis. Netrin-1 interactions with the cell surface were studied by flow cytometry. Netrin-1-targeted MBs were prepared using MicroMarker Target-Ready (VisualSonics), and validated in in vitro binding assays in static conditions or in a flow chamber using purified netrin-1 protein or netrin-1-expressing cancer cells. In vivo USMI of netrin-1 was validated in nude mice bearing human netrin-1-positive SKBR7 tumors or weakly netrin-1-expressing MDA-MB-231 tumors using the Vevo 2100 small animal imaging device (VisualSonics). USMI feasibility was further tested in transgenic murine FVB/N Tg(MMTV/PyMT634Mul) (MMTV-PyMT) mammary tumors. Results: Netrin-1 co-localized with endothelial CD31 in netrin-1-positive breast tumors. Netrin-1 binding to the surface of endothelial HUVEC and cancer cells was partially mediated by heparan sulfate proteoglycans. MBs targeted with humanized monoclonal anti-netrin-1 antibody bound to netrin-1-expressing cancer cells in static and dynamic conditions. USMI signal was significantly increased with anti-netrin-1 MBs in human SKBR7 breast tumors and transgenic murine MMTV-PyMT mammary tumors compared to signals recorded with either isotype control MBs or after blocking of netrin-1 with humanized monoclonal anti-netrin-1 antibody. In weakly netrin-1-expressing human tumors and normal mammary glands, no difference in imaging signal was observed with anti-netrin-1- and isotype control MBs. Ex vivo analysis confirmed netrin-1 expression in MMTV-PyMT tumors. Conclusions: These results show that USMI allowed reliable detection of netrin-1 on the endothelium of netrin-1-positive human and murine tumors. Significant differences in USMI signal for netrin-1 reflected the significant differences in netrin-1 mRNA & protein expression observed between different breast tumor models. The imaging approach was non-invasive and safe, and provided the netrin-1 expression status in near real-time. Thus, USMI of netrin-1 has the potential to become a companion diagnostic for the stratification of patients for netrin-1 interference therapy in future clinical trials.
A phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies
Authors: S. Blagden, P. Spiliopoulou, L. Spiers, C. Gnanaranjan, C. Qi, V.K. Woodcock, J. Moschandreas, H.E.J. Tyrrell, L. Griffiths, C. Butcher, E. Ghazaly, T.R.J. Evans
Journal: Annals of Oncology (2018)
An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23) - EORTC QLQ-BR45
Authors: V. Bjelic-Radisic, A. Bottomley, F. Cardoso, D. Cameron, E. Brain, K. Kuljanic, R.A. de Costa, T. Conroy, E. Inwald, S. Serpentini, M. Pinto, J. Weis, O. Morag, G. Guro Lindviksmoen Astrup, K. Tomaszweksi, K. Pogoda, P. Sinai, M.A.G. Sprangers, N. Aaronson, E. Greimel
Journal: Annals of Oncology (2018)
P3.01-57 Real-World (RW) Predictors of Immuno-Oncology (IO) vs Chemotherapy (C) Use in Advanced Non-Small Cell Lung Cancer (aNSCLC)
Authors: J. Radtchenko, B. Korytowsky, E. Nwokeji, K. Tuell, B. Feinberg
Journal: Journal of Thoracic Oncology (2018)
Trajectory of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) predicts time to progression (TTP) in metastatic colorectal cancer (mCRC) patients
Authors: S.A. Kurk, R.K. Stellato, P.H.M. Peeters, M. Oskam, B.D. Dorresteijn, M. Jourdan, C.J.A. Punt, M. Koopman, A.M. May
Journal: Annals of Oncology (2018)
P3.03-25 Squamous Cell Carcinoma-Associated Bronchial Dysplasias Demonstrate Altered T-helper Lymphocyte Differentiation
Authors: D. Merrick, E. Donald, Y. Miller, R. Keith, M. Ghosh, D. Aisner, K. Jordan, W. Franklin, J. Degregori
Journal: Journal of Thoracic Oncology (2018)
Abstract 16240: Mild Cognitive Impairment Across the Spectrum of Cardiovascular Disease
Authors: Jocasta Ball, Melinda J Carrington, Yih K Chan, Simon Stewart
Journal: Circulation (2017)

Introduction: Whilst it is known that mild cognitive impairment (MCI) can coexist in patients with cardiovascular disease (CVD), its impact across milder to more chronic forms and in those with mul...
P2.17-24 Does the Change in Body Mass Index During Induction Chemo/Chemoradiotherapy Affect the Outcome of Surgery in Locally Advanced NSCLC?
Authors: E. Ozer, G. Çetinkaya, A. Deligonul, H. Melek, T. Sevinç, E. Kurt, A.S. Bayram, T. Evrensel, C. Gebitekin
Journal: Journal of Thoracic Oncology (2018)
Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small cell lung cancer using next generation sequencing: A multicenter study
Authors: Q. Zhang, C. Xu, W. Wang, W. Zhuang, Z. Song, Y. Zhu, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Annals of Oncology (2018)
P2.13-21 MET Addiction Can be Circumvented Through EGFR Inhibition Via AXL in MET-Amplified Primary Resistant EGFR-Mutant NSCLCX.
Authors: L. Kwang, D. Lau, A. Liew, Y. Ju, E. Lim, G. Lai, R. Nahar, Y. Teng, K.P. Chua, J. Alvarez, M.J. Lim, H.S. Leong, F.T. Chong, D. Toh, H.S. Quah, L. Suteja, L.Y. Wang, K.H. Lim, W. Lim, E. Tan, W.W. Zhai, W.L. Tam, N.G. Iyer, D. Tan
Journal: Journal of Thoracic Oncology (2018)
The hippo pathway effector Yes‐associated protein promotes epithelial proliferation and remodeling in chronic rhinosinusitis with nasal polyps
Authors: Huiyi Deng, Yueqi Sun, Weihao Wang, Meijiao Li, Tian Yuan, Weifeng Kong, Xuekun Huang, Zijie Long, Zhuanggui Chen, Deyun Wang, Qintai Yang
Journal: Allergy (2018)

Hippo-Yes-associated protein (YAP) pathway plays an important role in epithelial cell proliferation and development. However, its possible role in chronic rhinosinusitis with nasal polyps (CRSwNP) remains unknown. We aim to investigate it on nasal epithelial proliferation and remodeling in CRSwNP.The expressions of hippo pathway components as well as Ki-67 and E-cadherin in the sinonasal mucosa and nasal epithelial cells were analyzed in 14 controls, 14 eosinophilic CRSwNP, and 14 noneosinophilic CRSwNP. Nasal epithelial cells from 6 controls, 6 eosinophilic CRSwNP, and 6 noneosinophilic CRSwNP were cultured and treated with lipopolysaccharide (LPS), Poly(I:C), or a selective YAP inhibitor verteporfin (VP).The hippo pathway components MST1, LATS1/2, YAP, and TEAD1 were increased in both eosinophilic and noneosinophilic CRSwNP, particularly in nasal epithelial cells, along with upregulation of Ki-67 and downregulation of E-cadherin. The mRNA levels of YAP positively correlated with the Ki-67 mRNA levels, and negatively associated with the E-cadherin mRNA levels in polyp tissues and epithelial cells from nasal polyps (NPECs). LPS and Poly(I:C) upregulated the YAP expression in nasal epithelial cells accompanied by increased TEAD1 and Ki-67 expression. Conversely, YAP inhibition by VP decreased TEAD1 and Ki-67 expression in NPECs.Hippo pathway components are abnormally upregulated in NPECs, and its effector YAP promotes nasal epithelial cells proliferation and remodeling in CRSwNP. It provides a rationale to explore inhibition of YAP as a novel therapeutic strategy for reducing the epithelial proliferation and remodeling in CRSwNP.
Reproducibility of the mRECIST criteria for the assessment of HCC treated by anti-VEGFR therapy: Impact of readers’ expertise
Authors: H. Beaumont, S. Egels, N. Faye, C. Klifa, A. Iannessi, E. Bonnard, O. Lucidarme
Journal: Annals of Oncology (2018)

Background: The imaging criteria mRECIST, which was initially introduced to assess the efficacy of HCC vascular bed destruction induced by TACE, is now often used to assess subtler vascular effects induced by anti-VEGFR therapy. However, variability of mRECIST assessment has been only partially investigated. In this study, we evaluated the inter-reader variability and its sources in the mRECIST assessment of treatment response for HCC treated by anti-VEGFR drugs. Methods: A subset of 41 advanced HCC tumors in 24 patients treated by anti-VEGFR drugs were selected from a phase I/II nalysedre study (the original study). These data were retrospectively reviewed according to mRECIST criteria by 3 mRECIST non-expert radiologists each having different levels of experience. Each liver lesion measurement was hand drawn using an electronic caliper. Results from these 3 radiologists were then compared to those extracted by an mRECIST expert at the time of the original study. The precision of measurements among the 3 non-experts and between the expert and the 3 non-experts were nalysed by assessing bias and standard deviation (SD) using the Bland-Altman method. The agreement of readers' responses was assessed using the Kappa coefficient statistic. The causes of discrepancies were nalysed. Results: Among the 3 non-experts, SD of measurements ranged [24.9%; 36.3%] and the Kappa coefficients were moderate 0.41 [0.28; 0.55]. SD in measurements of expert versus non-experts ranged [33.2%; 41.1%] and Kappa coefficients were poor 0.20 [0.06; 0.35]. Pooling the four readers together, the rate of discrepancy at declaring either Progressive Disease (PD) or Partial Response (PR) per patient was identical at 41.7% (10/24). The main cause of discrepancy at declaring PD came from the complexity of HCC enhancement patterns and the poor definition of tumors boundaries. Discrepancies at detecting PR came from the reader variability at selecting only the viable part or the entire liver tumor. Conclusions: When used by mRECIST non-experts to assess the subtle vascular effect induced on HCC by anti-VEGFR therapy, mRECIST appears to lack reproducibility. It is therefore important when using mRECIST to require specific training to reduce readers variability. Legal entity responsible for the study: Median Technologies. Funding: Has not received any funding. Disclosure: H. Beaumont, N. Faye, C. Klifa: Employee: Median Technologies. All other authors have declared no conflicts of interest.
A prospective study examining cachexia predictors in patients with incurable cancer
Authors: O.M. Vagnildhaug, C. Brunelli, M.J. Hjermstad, F. Strasser, V. Baracos, A. Wilcock, M. Nabal, S. Kaasa, B. Laird, T.S. Solheim
Journal: Annals of Oncology (2018)
P3.04-16 A Seven-Gene Expression Signature Reveals Unique Immune-Phenotypes Related to Major Oncogenic-Drivers in NSCLC
Authors: C. Teixidó, L. Pare, C. Aguado, S. Lopez, A. Giménez-Capitán, A. Cardona, C. Cabrera, S. Castillo, M. Garzón, C. Mayo, I. Sullivan, S. Muñoz, G. Castellano, P. Jares, A. Prat, M. Molina-Vila, N. Reguart
Journal: Journal of Thoracic Oncology (2018)
Clinical relevance of circulating tumor DNA using amplicon-based deep sequencing panel in colorectal cancer patients with liver metastasis
Authors: H. Osumi, E. Shinozaki, H. Zembutsu, Y. Takeda, T. Wakatsuki, T. Ichimura, Y. Ota, I. Nakayama, M. Ogura, M. Suenaga, D. Takahari, K. Chin, A. Saiura, S. Takahashi, T. Noda, K. Yamaguchi
Journal: Annals of Oncology (2018)
Theory-Based Health Behavior Interventions for Pediatric Chronic Disease Management
Authors: Chun Y. Ng, Monika Thomas-Uribe, Yvonne A. Yang, Michael CY Chu, Shih-Dun Liu, Uma Palam Pulendran, Bea-Jane Lin, Dorie S. Lerner, Abby C. King, C. Jason Wang
Journal: JAMA Pediatrics (2018)

Pediatric chronic conditions have become a major public health challenge, and behavioral change plays an important role in overcoming this problem. Many health behavior interventions are described as theory-based, but evidence that such programs properly use theoretical constructs is scant.To identify effective theory-based behavioral interventions that motivate patients and families to adopt better self-management behaviors for chronic disease, to review theoretical constructs from each theory and identify the common elements for action, and to rate the level of evidence for each theory-based chronic disease intervention.Medline and PsycINFO electronic databases were searched for relevant randomized clinical trial articles published between January 1, 2000, and June 30, 2016, with English language and article type restrictions. These articles reported original data on children and young adults aged 21 years or younger, measured interventions for a pediatric chronic health problem, and assessed the association between interventions and health behavior, knowledge, and outcomes. The Jadad scale was used to evaluate the methods of each article. Articles that explicitly identified the theoretical basis for the intervention and scored 3 points or higher on the Jadad scale were included in the final analysis.The database search yielded a total of 36 187 articles, from which duplicates and those that did not meet the inclusion criteria were eliminated, leaving 129 studies for the full review. Of the 129 studies, 29 (22.5%) had higher Jadad scale scores of 3 or 4 points and underwent the final detailed data abstraction and qualitative synthesis. Five chronic conditions were represented, including asthma (55% [16 of 29]), type 1 diabetes (21% [6 of 29]), obesity (14% [4 of 29]), attention-deficit/hyperactivity disorder (7% [2 of 29]), and autistic spectrum disorder (3% [1 of 29]). Most studies (55% [16 of 29]) used Social Cognitive Theory as the theoretical basis for intervention. The following intervention outcomes were reported: 23 (80%) saw a positive association with health-related behaviors (eg, adherence), 8 (28%) with knowledge, 7 (24%) with attitudes, and 26 (90%) with clinical outcomes. Ten studies (34%) showed results in both health behaviors and health outcomes. Twenty-two studies (76%) demonstrated short-term effects (within 6 months), whereas 12 (41%) reported longer-term changes.Identifying effective theory-based behavioral interventions can empower those who are involved in the care of children and young adults with chronic conditions.
Response evaluation of cancer therapeutics in metastatic breast cancer to the bone: A single arm phase II study of whole-body magnetic resonance imaging
Authors: M. Kosmin, A.R. Padhani, A. Gogbashian, D. Woolf, M.-L. Ah-See, P. Ostler, S. Sutherland, D. Miles, J. Noble, A. Marshall, J. Dunn, A. Makris
Journal: Annals of Oncology (2018)
P1.13-24 EGFR-KDD is Rare and Demonstrates Variable Anti-Tumor Response to Tyrosine Kinase Inhibitors in East Asian NSCLC Population
Authors: J. Wang, Q. Ou, X. Xue, Y. Liang, X. Wu, X. Wang, M. You, Y. Shao
Journal: Journal of Thoracic Oncology (2018)
Compliance with the criteria of involuntary admission in China's Mental Health Law: a national cross-sectional study of patients admitted to hospital involuntarily
Authors: Feng Jiang, Huixuan Zhou, Linlin Hu, Tingfang Liu, Shichao Wu, Pengyu Zhao, Guangyu Hu, Huanzhong Liu, Yilang Tang, Yuanli Liu
Journal: The Lancet (2018)
Prospective comprehensive genomic profiling (CGP) of 3,343 primary and metastatic site prostate tumors
Authors: S.M. Ali, J. Chung, N. Dewal, L.M. Gay, Y. He, E.S. Sokol, S.Z. Millis, J.K. Killian, A.B. Schrock, S.K. Pal, V.A. Miller, J.S. Ross, N. Agarwal
Journal: Annals of Oncology (2018)
Patients in research: one step in a long path
Authors: Scott A Lear
Journal: BMJ (2018)

The BMJ encourages the engagement of patients in the design and conduct of research. As Wicks and colleagues say, funding agencies often include patients on grant review committees.1 These patients, however, have little input into funding decisions. One excuse is that patients do not understand research. But why can’t we train them to do so? Patients are more than their disease. They …
P2.01-70 Tumor Treating Fields and Radiosurgery for Supra- and/or Infratentorial Brain Metastases (1-10) from NSCLC in the Phase 3 METIS Study
Authors: M. Mehta, V. Gondi, M. Ahluwalia, P. Brown, U. Weinberg
Journal: Journal of Thoracic Oncology (2018)
Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE
Authors: C.C. Parker, N.D. James, C. Brawley, N.W. Clarke, G. Attard, S. Chowdhury, W. Cross, D.P. Dearnaley, C.E. Gilson, R. Jones, M.D. Mason, R. Millman, S. Gillessen, C. Eswar, J. Gale, J. Lester, D. Sheehan, A. Tran, M.K. Parmar, M.R. Sydes
Journal: Annals of Oncology (2018)
Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis
Authors: S. Kümmel, C.A. Tondini, J. Abraham, Z.I. Nowecki, B. Itrych, E. Hitre, B. Karaszewska, A. Juarez, F. Morales-Vásquez, J.M. Pérez García, S. Cardona-Huerta, D. Heinzmann, J. He, A.N. Duc, A. Crepelle-Fléchais, M. Martín
Journal: Annals of Oncology (2018)
Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO)
Authors: R. Ferrara, M. Naigeon, E. Auclin, B. Duchemann, L. Cassard, J. Medhi, L. Boselli, J. Grivel, A. Desnoyer, L. Mezquita, F. Aboubakar, L. Hendriks, D. Planchard, C. Caramella, J. Remon, M. Ngocamus, C. Nicotra, B. Besse, N. Chaput
Journal: Annals of Oncology (2018)
Ostracism in adolescent cancer patients and predictors (OSTRACA Study): A study of the palliative care working committee of the Turkish Oncology Group (TOG)
Authors: A. Alkan, Z.G. Güç, T. Şakalar, G. Zengin, A. Yaşar, Y. Karakas, T. Yavuzsen, O.B. Oksuzoglu, F. Çay Şenler
Journal: Annals of Oncology (2018)
JCSE01.18 A Multicenter Survey of One Year Survival Among Chinese Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer (CTONG1506)
Authors: P. Yu, Q. Zhou, Y. Song, X. Zhang, G. Chen, Y. Zhang, J. Chen, Z. Yu, Y. Hu, X. Song, D. Zhong, G. Feng, L. Yang, L. Zhan, L.D. Yao, Y. Chen, Y. Gao, Y. Wu
Journal: Journal of Thoracic Oncology (2018)
Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)
Authors: F.S. Hodi, V. Chiarion-Sileni, R. Gonzalez, J.J. Grob, P. Rutkowski, C.L. Cowey, C. Lao, D. Schadendorf, J. Wagstaff, R. Dummer, P.F. Ferrucci, M. Smylie, A.G. Hill, D. Hogg, I. Marquez-Rodas, J. Jiang, J. Rizzo, J. Larkin, J. Wolchok
Journal: Annals of Oncology (2018)
P3.01-100 Risk of Gastrointestinal and Hepatic Toxicities in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Osimertinib
Authors: K. Thein, S. Swarup, S. Ball, M. Quirch, Y. Vorakunthada, S. Khan, F. Hardwicke, S. Awasthi, L. Tijani
Journal: Journal of Thoracic Oncology (2018)
Australian health professionals' statement on climate change and health
Authors: Kerry Arabena, Fiona Armstrong, Helen Berry, Peter Brooks, Tony Capon, Brendan Crabb, Alessandro Demaio, Peter Doherty, Sharon Lewin, Selina Lo, Alan Lopez, Celia McMichael, Barbara McPake, Rob Moodie, Terry Nolan, Tilman Ruff, Peter Sainsbury, Linda Selvey, David Shearman, Fiona Stanley, Nicholas J Talley, Nick Watts
Journal: The Lancet (2018)
Allergological workup with half‐dose challenge in iodinated contrast media hypersensitivity
Authors: Angèle Soria, Nathalie Masson, Amandine Vial‐Dupuy, Hafida Gaouar, Emmanuelle Amsler, Sylvie Chollet‐Martin, Pascale Nicaise‐Roland, Jean‐Eric Autegarden, Annick Barbaud
Journal: Allergy (2018)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Early results from an open-label phase 1b/II study of eribulin mesylate (EM) + pegvorhyaluronidase alfa (PEGHP20) combination for the treatment of patients with HER2-negative, high-hyaluronan (HA) metastatic breast cancer (MBC)
Authors: M. Shum, V.J. Assikis, C. Savulsky, W. Zhu, P. Iyer, D. Xing, C. Berman, N.A. Lokker, R.H. Alvarez
Journal: Annals of Oncology (2018)
P1.01-66 Randomized Phase II Evaluating EGFR-TKI Associated with Anti-Estrogen in Women with Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial
Authors: J. Mazieres, F. Barlesi, I. Rouquette, B. Besse, I. Monnet, C. Audigier-Valette, A. Toffart, A. Renault, S. Moreau, S. Hiret, B. Mennecier, D. Debieuvre, V. Westeel, P. Masson, A. Madroszyk, E. Amour, F. Morin, G. Zalcman, D. Moro-Sibilot, P.J. Souquet
Journal: Journal of Thoracic Oncology (2018)